Drug Trial Radar · NCT01773187
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Last checked: Nov 20, 2026Latest source record: Sep 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
327
Actual
Start
Jan 2013
Primary completion
Jan 2015
Study completion Apr 2016
Sponsor
- Lead sponsor
- CTI BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- Jan 23, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.
Conditions
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
Interventions
PacritinibDrug
Best Available TherapyDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Spleen Volume ReductionTime frame: Baseline to Week 24
Locations
81 sites in 12 countries. Site status is shown where the registry gives one.
CTI Investigational Site 10002
Scottsdale, Arizona
CTI Investigational Site 10004
Omaha, Nebraska
CTI Investigational Site 10001
Morristown, New Jersey
CTI Investigational Site 10003
Greenville, South Carolina
CTI Investigational Site 61006
Box Hill, Australia
CTI Investigational Site 61001
Coffs Harbour, Australia
CTI Investigational Site 61005
Geelong, Australia
CTI Investigational Site 61003
Gosford, Australia
CTI Investigational Site 61004
Hobart, Australia
CTI Investigational Site 61002
Milton, Australia
CTI Investigational Site 32002
Antwerp, Belgium
CTI Investigational Site 32003
Antwerp, Belgium
CTI Investigational Site 32001
Bruges, Belgium
CTI Investigational Site 32005
Brussels, Belgium
CTI Investigational Site 32004
La Louvière, Belgium
CTI Investigational Site 42003
Brno, Czechia
CTI Investigational Site 42001
Olomouc, Czechia
CTI Investigational Site 42002
Pilsen, Czechia
CTI Investigational Site 42004
Prague, Czechia
CTI Investigational Site 33005
Amiens, France
CTI Investigational Site 33006
Caen, France
CTI Investigational Site 33011
Grenoble, France
CTI Investigational Site 33012
Lens, France
CTI Investigational Site 33007
Lille, France
CTI Investigational Site 33001
Nîmes, France
CTI Investigational Site 33004
Paris, France
CTI Investigational Site 33008
Paris, France
CTI Investigational Site 33009
Pessac, France
CTI Investigational Site 33010
Pierre-Bénite, France
CTI Investigational Site 33003
Strasbourg, France
CTI Investigational Site 33002
Toulouse, France
CTI Investigational Site 49006
Berlin, Germany
CTI Investigational Site 49007
Berlin, Germany
CTI Investigational Site 49001
Cologne, Germany
CTI Investigational Site 49003
Dresden, Germany
CTI Investigational Site 49008
Essen, Germany
CTI Investigational Site 49002
Freiburg im Breisgau, Germany
CTI Investigational Site 49005
Mainz, Germany
CTI Investigational Site 49004
München, Germany
CTI Investigational Site 49009
Münster, Germany
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.